Melanoma
IL-2 "SELECT" for Advanced Melanoma
The High-Dose Aldesleukin (IL-2) "SELECT" Trial: A Prospective Tissue Collection Protocol to Investigate Predictive Models of Response to High-Dose IL-2 Treatments in Patients With Advance Melanoma
| Status | Conditions | Phase | Study ID |
| Recruiting | Malignant Melanoma | N/A | NCT01288963 |
Summary
The purpose of this study is to determine which participants with melanoma have a better response to IL-2 and to identify markers that may predict response to IL-2 by collecting participant information (for example; cancer diagnosis and history, prior treatments for cancer, etc.) blood and tumor samples prior to treatment and tumor measurements after treatment.
|
|
Eligibility Criteria (must meet the following to participate in this study)
| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Study Population
Subjects enrolled on DF/HCC Protocol 06-149
Criteria
Inclusion Criteria:
- Malignant melanoma that is metastatic or unresectable
- Eligible to receive high-dose IL-2
- Tissue block available with adequate tumor to perform RNA extraction and DASL analysis
Exclusion Criteria:
- Prior immunotherapy for unresectable or metastatic disease
- Untreated brain metastases, leptomeningeal disease, or seizure disorder
Last Updated
November 23, 2011See this trial at ClinicalTrials.gov
Access protocol and consent forms at Fred Hutchinson Cancer Research Center
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Please remember:
Please remember:
- Talk to your health care providers first before making decisions about your health care.
- Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.
Join Us On